{"url_path":"/sec/cue/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 OTHER INFORMATION","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1645460/0001193125-26-224091-index.html","accession_number":"0001193125-26-224091","cik":"0001645460","ticker":"CUE","issuer_name":"Cue Biopharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1645460/0001193125-26-224091-index.html","primary_entity_key":"0001645460","primary_entity_name":"Cue Biopharma, Inc."},"word_count":47,"has_tables":true,"body_markdown":"ITEM 5. OTHER INFORMATION\n\n \n\n(c) Director and Officer Trading Arrangements\n\nNone of our directors or officers adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K) during the quarterly period covered by this report.\n\n47"}